Filing Flows

Filing Flows › Companies › Corcept Therapeutics › Cash flow

Corcept Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$142M in Q3 2026 · $195M over twelve months

Operating cash flow$143M
Capital spending−$709K
Free cash flow+$142M
Cash / net income1.1×
Cash conversion cycle-92 days

Analysis

In Q3 2026, Corcept Therapeutics generated $143M of operating cash flow and spent $709K on capital projects, leaving free cash flow of $142M. That is $87.7M more than in Q3 2025 ($54.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was $198M; the largest uses were other investing ($165M), taxes on employees’ shares ($91.7M), buybacks ($5.7M); besides operations, cash came from shares issued ($29.6M), other financing ($11.5M); the cash balance fell by $27.0M.

Operating cash flow was $143M against net income of $127M — 1.1× profit, cash ran ahead of reported earnings. The largest differences: receivables −$34.1M, stock-based pay +$29.4M, accrued liabilities +$11.1M.

Its cash conversion cycle was -92 days (receivables 25 + inventory 250 − payables 368): suppliers fund its working capital.

Free cash flow

Corcept Therapeutics: free cash flow by quarterCorcept Therapeutics: free cash flow by quarter$59.9MQ4 2024$4.7MQ1 2025$44.2MQ2 2025$54.5MQ3 2025$38.4MQ4 2025−$17.0MQ1 2026$31.0MQ2 2026$142MQ3 2026
Operating cash flow less capital spending.
Corcept Therapeutics: operating cash flow against capital spendingCorcept Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending$60.1M$121KQ4 2024$4.8M$104KQ1 2025$44.3M$57KQ2 2025$54.5M$0Q3 2025$38.4M$50KQ4 2025−$16.8M$201KQ1 2026$33.5M$2.5MQ2 2026$143M$709KQ3 2026
Latest (Q3 2026): Operating cash flow $143M, Capital spending $709K.

Capital allocation, year by year

Corcept Therapeutics: where the cash came from (up) and went (down), by fiscal yearCorcept Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingBuybacksFY2021: Operating cash flow $168MFY2021: Shares issued $16.2MFY2021: Capital spending −$469K$184MFY2021FY2022: Operating cash flow $120MFY2022: Shares issued $4.4MFY2022: Capital spending −$413K$125MFY2022FY2023: Operating cash flow $127MFY2023: Shares issued $5.8MFY2023: Capital spending −$139K$132MFY2023FY2024: Operating cash flow $198MFY2024: Shares issued $4.2MFY2024: Capital spending −$2.2MFY2024: Buybacks −$15.7M$202MFY2024FY2025: Operating cash flow $142MFY2025: Shares issued $15.9MFY2025: Capital spending −$211KFY2025: Buybacks −$173M$158MFY2025
Over these 5 years operating cash flow totalled $755M; the largest uses were buybacks ($189M) and capital spending ($3.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$371M
Debtnone
Net cash$371M

Corcept Therapeutics funds itself: free cash flow was $195M over the last twelve months, with $371M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Corcept Therapeutics: sources (+) and uses (−) of cash, Q3 2026Corcept Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$143MOther investing−$131MTaxes on employees’ shares−$37.9MShares issued$16.9MCash drawn (+) / kept (−)$12.9MBuybacks−$5.7MOther financing$2.9MCapital spending−$709KExchange rates$78K
Corcept Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Corcept Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$198MOther investing−$165MTaxes on employees’ shares−$91.7MShares issued$29.6MCash drawn (+) / kept (−)$27.0MOther financing$11.5MBuybacks−$5.7MCapital spending−$3.5MExchange rates−$204K

From profit to cash

Corcept Therapeutics: net income to operating cash flow, Q3 2026Corcept Therapeutics: net income to operating cash flow, Q3 2026Net income$127MDepreciation & amortization$1.0MStock-based pay$29.4MDeferred taxes$9.6MReceivables−$34.1MInventory−$5.1MPayables$7.3MAccrued liabilities$11.1MPrepaid and other assets$1.1MOperating cash flow$143M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202625250368-92
Q2 202621292540-227
Q1 2026274021151-722
Q4 2025294561354-868
Q3 202530246580-304
Q2 202530353682-299
Q1 202533501811-277
Q4 202429318528-181

Every quarter

QuarterOperating cash flowCapital spendingBuybacksShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$143M−$709K−$5.7M$16.9M$12.9M$142M
Q2 2026$33.5M−$2.5M—$5.8M−$2.3M$31.0M
Q1 2026−$16.8M−$201K—$4.0M$11.8M−$17.0M
Q4 2025$38.4M−$50K—$2.9M$4.6M$38.4M
Q3 2025$54.5M—−$42.5M$2.0M−$22.4M$54.5M
Q2 2025$44.3M−$57K−$103M$9.2M−$12.9M$44.2M
Q1 2025$4.8M−$104K−$27.4M$1.7M$37.8M$4.7M
Q4 2024$60.1M−$121K—$889K$9.6M$59.9M

Corcept Therapeutics: income statement and cash flow

Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%. The chart follows the revenue to costs, profit and cash.

Corcept Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.